XML 146 R52.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration Agreements - Summary of Total Consolidated Net Revenues from Strategic Collaborators (Details) - Collaboration Revenue by Strategic Collaborator - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue $ 74,618 $ 48,036  
Balance without adoption of ASC 605      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue     $ 122,512
Merck      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue 26,076 36,608  
Merck | Balance without adoption of ASC 605      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue     66,082
AstraZeneca      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue 32,624 5,233  
AstraZeneca | Balance without adoption of ASC 605      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue     45,993
Vertex      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue 15,505 6,195  
Vertex | Balance without adoption of ASC 605      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue     10,437
Other      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue $ 413 $ 0  
Other | Balance without adoption of ASC 605      
New Accounting Pronouncements or Change in Accounting Principle [Line Items]      
Total collaboration revenue     $ 0